Categories AlphaGraphs, Earnings, Health Care
Gilead Sciences reports Q3 earnings. Here’s everything you need to know
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, on Tuesday reported financial results for the third quarter of 2023.
Revenues came in at $7.05 billion in the September quarter, compared to $7.04 billion in the corresponding period of 2022. For fiscal 2023, the company expects product revenues to be in the range of $26.7 billion to $26.9 billion.
Adjusted net income was $2.29 per share in the third quarter, vs. $1.90 per share in the prior-year period. The company reported an unadjusted profit of $2.18 billion or $1.75 per share for the quarter, compared to $1.79 billion or $1.43 per share in Q3 2022.
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs